369 related articles for article (PubMed ID: 29717036)
1. PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol.
Walsh JA; Arledge T; Nurminen T; Peterson L; Stark J
J Rheumatol; 2018 Jul; 45(7):922-928. PubMed ID: 29717036
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.
Duffin KC; Papp KA; Bagel J; Levi E; Chen R; Gottlieb AB
J Drugs Dermatol; 2017 Feb; 16(2):147-153. PubMed ID: 28300857
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis.
Carubbi F; Fidanza R; Palmieri M; Ventura A; Tambone S; Cipriani P; Giacomelli R; Fargnoli MC
J Dermatolog Treat; 2020 Nov; 31(7):692-697. PubMed ID: 30963798
[No Abstract] [Full Text] [Related]
5. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
Mease PJ; Fleischmann R; Deodhar AA; Wollenhaupt J; Khraishi M; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; van der Heijde D
Ann Rheum Dis; 2014 Jan; 73(1):48-55. PubMed ID: 23942868
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life.
Dattola A; Mazzeo M; Di Stefano F; Manfreda V; Vollono L; Di Raimondo C; Di Matteo E; Bianchi L
Dermatol Ther; 2020 May; 33(3):e13409. PubMed ID: 32291887
[TBL] [Abstract][Full Text] [Related]
7. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
8. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort.
Walsh JA; McFadden M; Woodcock J; Clegg DO; Helliwell P; Dommasch E; Gelfand JM; Krueger GG; Duffin KC
J Am Acad Dermatol; 2013 Dec; 69(6):931-7. PubMed ID: 24054760
[TBL] [Abstract][Full Text] [Related]
9. PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.
Gold LS; Hansen JB; Patel D; Veverka KA; Strober B
J Am Acad Dermatol; 2020 Jul; 83(1):131-138. PubMed ID: 32430142
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab pegol in the treatment of psoriasis: Real-life data.
Turkmen M; Dogan S
Dermatol Ther; 2021 May; 34(3):e14929. PubMed ID: 33665940
[TBL] [Abstract][Full Text] [Related]
11. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment.
Chow C; Simpson MJ; Luger TA; Chubb H; Ellis CN
J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1406-14. PubMed ID: 25917315
[TBL] [Abstract][Full Text] [Related]
12. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study.
Gladman D; Fleischmann R; Coteur G; Woltering F; Mease PJ
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1085-92. PubMed ID: 24339179
[TBL] [Abstract][Full Text] [Related]
13. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis.
Esposito M; Carubbi F; Giunta A; Alunno A; Giacomelli R; Fargnoli MC
Expert Rev Clin Immunol; 2020 Feb; 16(2):119-128. PubMed ID: 31917928
[No Abstract] [Full Text] [Related]
14. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
15. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.
Kavanaugh A; Gladman D; van der Heijde D; Purcaru O; Mease P
Ann Rheum Dis; 2015 Jan; 74(1):44-51. PubMed ID: 24942382
[TBL] [Abstract][Full Text] [Related]
16. Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers.
Vender RB; Lynde CW
J Cutan Med Surg; 2022; 26(3):267-273. PubMed ID: 35134313
[TBL] [Abstract][Full Text] [Related]
17. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
18. [Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol.
Ruiz AN; Alberola FT; Aceituno S;
Farm Hosp; 2024; 48(2):T51-T56. PubMed ID: 38148255
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Gordon KB; Warren RB; Gottlieb AB; Blauvelt A; Thaçi D; Leonardi C; Poulin Y; Boehnlein M; Brock F; Ecoffet C; Reich K
Br J Dermatol; 2021 Apr; 184(4):652-662. PubMed ID: 32652544
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P
Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
